Moderna is developing a three-in-one vaccine against COVID-19, flu and RSV. The vaccine manufacturer is actively promoting the shot and hoping for regulatory approval in the next year.

Moderna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7 per cent effective in a late-stage trial at preventing at least two symptoms ...

Moderna (MRNA) skyrocketed to fame during the pandemic, delivering one of the first mRNA-based Covid-19 vaccines and quickly ...

In its news release, Moderna said its mRNA vaccine is the first RSV shot to come in a pre-filled syringe and says that will save time for health-care workers and reduce any errors in administering it.

In its news release, Moderna said its mRNA vaccine is the first RSV shot to come in a pre-filled syringe and says that will save time for health-care workers and reduce any errors in administering it.

Moderna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as ...

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

Moderna's RSV candidate First, a bit of background on Moderna's RSV candidate. RSV generally causes cold-like symptoms, but the virus could be severe for certain groups like elderly people or infants.

Moderna said it intends to submit its vaccine, mRNA-1345, for regulatory approval consideration globally in the first half of 2023. The company's president, Stephen Hoge, told Reuters that its vaccine ...

In its news release, Moderna said its mRNA vaccine is the first RSV shot to come in a pre-filled syringe and says that will save time for health-care workers and reduce any errors in administering it.